<DOC>
	<DOC>NCT00515554</DOC>
	<brief_summary>This study is designed to test: 1. in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles) 2. for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.</brief_summary>
	<brief_title>HD18 for Advanced Stages in Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Hodgkin Lymphoma (histologically proven) CS (PS) IIB with one or both of the risk factors: bulky mediastinal mass (&gt; 1/3 of maximum transverse thorax diameter) extranodal involvement CS (PS) III, IV Written informed consent Leucocytes &lt; 3000/µl Platelets &lt; 100000/µl Hodgkin´s lymphoma as "composite lymphoma" Activity index (WHO) &lt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>PET</keyword>
	<keyword>advances stages</keyword>
	<keyword>Rituximab</keyword>
</DOC>